Isosorbide Dinitrate in Experimental Portal Hypertension: A Study of Factors That Modulate the Hemodynamic Response

Open Access
Publisher Website
Google Scholar
Abstract
Isosorbide dinitrate, a long–acting vasodilator, has been tested in human portal hypertension with conflictingresults. In order to determine some of the factors that could affect the individual response to this drug, we infused isosorbide dinitrate at a low dose (10 to 25 μg per kg per min) and a high dose (100 μg per kg per min) to rats with portal vein stenosis. Under pentobarbital anesthesia, portal pressure was measured with an ileocolic vein catheter while cardiac output and regional blood flows were measured with the microsphere technique. At a dose that decreased arterial pressure by approximately 10%, cardiac output remained unchanged while portal vein inflow decreased significantly; portal pressure was not reduced (10.7 ± 0.2 vs. 10.0 ± 0.3 mm Hg), indicating a rise in portal vascular resistance. At a high dose of isosorbide dinitrate, arterial pressure and cardiac output fell markedly; portal pressure decreased only modestly (11.3 ± 0.3 vs. 9.8 ± 0.6 mm Hg, p < 0.05), but portal flow was unchanged, indicating a reduction in portal vascular resistance. In addition, portal hypertensive rats received a constant i.v. infusion of N–acetyl–cysteine the combination of the latter and isosorbide dinitrate markedly potentiated the effects on arterial pressure. Thus, the dose of the drug and the presence of cysteine–containing compounds appear to modulate the hemodynamic response to isosorbide dinitrate. Clinical testing with this drug should be undertaken with consideration of these factors.